CagriSema REDEFINE 2: Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Phase 2 dose-finding data The phase 2 trial tested cagrilintide at 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, and 4.5 mg weekly
An expert can help you avoid common tax mistakes
See the Bridge guide for eligible plan types
Retatrutide represents a significant advancement in pharmacological intervention for metabolic disorders
This week, direct-to-patient healthcare company Ro made it easier for those patients to find where to get their meds with the launch of the GLP-1 Supply Tracker, an interactive tool that provides real-time insights on GLP-1 drug shortages, along with automated, localized supply alerts